- Dr Lal PathLabs reported a 28.8% YoY rise in Q1FY27 net profit to Rs 170 crore
- Revenue grew 19.1% YoY to Rs 798 crore for the quarter ended June 2026
- EBITDA increased 28.7% to Rs 248 crore with margin improving to 31%
Diagnostic services provider Dr Lal PathLabs reported a strong set of earnings for the quarter ended June 2026, with double-digit growth in revenue and profitability.
The company's consolidated net profit rose 28.8% year-on-year (YoY) to Rs 170 crore in Q1FY27, compared with Rs 132 crore in the corresponding quarter last year.
Revenue from operations, or topline, increased 19.1% YoY to Rs 798 crore from Rs 670 crore a year ago.
ALSO READ: Manipal Hospital IPO 'Just An Event'; Temasek Bullish On Healthcare Run: Ravi Lambah
At the operating level, earnings before interest, tax, depreciation and amortisation (EBITDA) climbed 28.7% to Rs 248 crore, compared with Rs 192 crore in the year-ago quarter. EBITDA margin improved to 31% from 28.7% in Q1FY26.
The company's board also approved an interim dividend of Rs 5 per equity share for the financial year 2026-27.
“The record date for the purpose of payment of Interim Dividend shall be July 30, 2026. The Interim Dividend will be paid within 30 days of its declaration,” the company said.
Meanwhile, on the bourses at around 1:55 pm, Dr Lal PathLabs shares were trading 0.31% higher at Rs 1,691.90 per share. By comparison, BSE Sensex was trading 0.45% lower at 76,046 levels.
ALSO READ: Manipal IPO Likely To Open Early Next Week; Temasek To Be Largest Seller In OFS
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
